Pivotal Relative Bioavailability Study to Investigate the Pharmacokinetics and Food Effect of Single Oral Doses of Vericiguat Given as Pediatric Oral Suspension Formulations in Comparison to the 10 mg IR Tablet in Healthy Male Participants in a Randomized, Open-label, 4-fold Crossover Design
Latest Information Update: 07 Feb 2023
Price :
$35 *
At a glance
- Drugs Vericiguat (Primary) ; Vericiguat
- Indications Heart failure
- Focus Pharmacokinetics; Registrational
- Sponsors Bayer
- 21 Feb 2022 Status changed from active, no longer recruiting to completed.
- 18 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 27 Oct 2021 Status changed from not yet recruiting to recruiting.